In particular, the doxorubicin-induced immunogenic cell death releases TLR2-activating DAMPs, such as HMGB1, able to protects breast cancer cells from chemotherapy and promotes metastasis formation (105). This evidence concerns the gene TLR2 and breast carcinoma.